Health authorities in the UK have moved to rename polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS), citing the new terminology as more representative of how the condition affects the entire body rather than just reproductive organs. The change has been accompanied by recommendations for annual health reviews to enhance ongoing monitoring and care for women living with the condition.
PCOS, which affects millions of women in the UK, can impact menstruation, fertility, hair growth and mood. Medical experts have characterized it as fundamentally a cardiometabolic condition requiring a holistic approach to treatment and monitoring. In July, the National Institute for Health and Care Excellence (NICE) published draft guidance recommending that women with PMOS receive annual reviews to track symptoms, monitor treatment effectiveness and assess longer-term health risks. NICE officials stated the recommendation aimed to improve consistency of care, increase awareness and support earlier diagnosis and management, with final guidelines scheduled for publication on 27 January.
Women with lived experience of the condition have welcomed the changes while noting significant gaps remain in current care practices. Many report receiving minimal guidance or support after initial diagnosis and describe fragmented healthcare services that fail to address the condition comprehensively. Advocates emphasize that annual check-ups should examine multiple health markers including diabetes risk, thyroid function and menstrual health, rather than focusing narrowly on weight management. Medical professionals have stressed that PMOS is a lifelong, multi-organ condition affecting a substantial proportion of women at healthy weights, underscoring the need for individualized, comprehensive care approaches rather than one-size-fits-all interventions.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI